Inhibitors of Hsp90

Details for Australian Patent Application No. 2005266493 (hide)

Owner Novartis AG

Inventors Floersheimer, Andreas; Furet, Pascal; Chene, Patrick; Schoepfer, Joseph

Agent Davies Collison Cave

Pub. Number AU-B-2005266493

PCT Pub. Number WO2006/010594

Priority 60/591,330 27.07.04 US

Filing date 26 July 2005

Wipo publication date 2 February 2006

Acceptance publication date 10 September 2009

International Classifications

A61K 31/4184 (2006.01)

A61P 35/00 (2006.01) Antineoplastic agents

A61P 35/02 (2006.01) Antineoplastic agents

C07D 239/70 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

Event Publications

8 February 2007 PCT application entered the National Phase

  PCT publication WO2006/010594 Priority application(s): WO2006/010594

10 September 2009 Application Accepted

  Published as AU-B-2005266493

14 January 2010 Standard Patent Sealed

23 February 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005266494-Inhibitors of Hsp90

2005266490-Quinazoline derivatives